Remove 2030 Remove Chemotherapy Remove Pharmaceutical Companies
article thumbnail

Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030

Express Pharma

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate cancer. billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. billion by 2030. bn in sales by 2030 appeared first on Express Pharma.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%